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Current guidelines lack comprehensive information on the metastatic site-specific role of KRAS 
mutation in lung adenocarcinoma (LADC). We investigated the effect of KRAS mutation on overall 
survival (OS) in this setting. In our retrospective study, 500 consecutive Caucasian metastatic LADC 
patients with known KRAS mutational status were analyzed after excluding 32 patients with EGFR 
mutations. KRAS mutation incidence was 28.6%. The most frequent metastatic sites were lung 
(45.6%), bone (26.2%), adrenal gland (17.4%), brain (16.8%), pleura (15.6%) and liver (11%). Patients 
with intrapulmonary metastasis had significantly increased KRAS mutation frequency compared to 
those with extrapulmonary metastases (35% vs 26.5%, p = 0.0125). In contrast, pleural dissemination 
and liver involvement were associated with significantly decreased KRAS mutation incidence (vs all 
other metastatic sites; 17% (p < 0.001) and 16% (p = 0.02) vs 33%, respectively). Strikingly, we found 
a significant prognostic effect of KRAS status only in the bone metastatic subcohort (KRAS-wild-type 
vs KRAS-mutant; median OS 9.7 v 3.7 months; HR, 0.49; 95% CI, 0.31 to 0.79; p  = 0.003). Our study 
suggests that KRAS mutation frequency in LADC patients shows a metastatic site dependent variation 
and, moreover, that the presence of KRAS mutation is associated with significantly worse outcome in 
bone metastatic cases.
Oncogenic mutations of the Kirsten rat sarcoma viral oncogene homolog gene (KRAS) are frequently identified 
in lung, colorectal and pancreatic cancers1. In lung adenocarcinoma (LADC), the mutation rate was found to be 
up to 30%2–5. KRAS is a proto-oncogene that is a downstream member of the epidermal growth factor receptor 
(EGFR) signaling pathway. KRAS and EGFR activating mutations have been described to be usually mutually 
exclusive6.
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While extensive data is available on the predictive and prognostic significance of KRAS mutation in colorectal 
carcinoma (CRC), we have ambiguous information on its prognostic role in lung cancer. In CRC, the presence of 
KRAS mutation is associated with increased metastatic potential and lack of treatment benefit from anti-EGFR 
monoclonal antibody therapy7,8. CRC patients with KRAS-mutant tumors have worse overall survival (OS) and 
increased incidence of lung, bone and brain metastasis9–11. Accordingly, Zou et al. found that KRAS mutations 
might be used as independent predictors of distant metastases in CRC12. Moreover, KRAS mutations in CRC 
patients were significantly associated with the number of pulmonary metastasis and with the lung as first site 
of recurrence after pulmonary metastasectomy13. Besides, KRAS mutation has been reported to be a potential 
negative prognostic factor in patients with liver metastatic colorectal cancer in various treatment modalities14–16.
Although the role of KRAS mutations in non-small cell lung cancer (NSCLC) is intensely investigated, there is 
limited and partly contradictory information on its prognostic role in lung cancer5,17–19. A recent pooled analysis 
including 1362 patients from four EGFR-TKI randomized controlled trials failed to show a survival difference in 
the placebo arm between patients with KRAS-mutated and wild-type tumors19. Moreover, our group has recently 
demonstrated that KRAS mutation status per se is not prognostic in platinum based chemotherapy treated unre-
sected stage III–IV LADC5. On the other hand, several other studies including large meta-analyses demonstrated 
that KRAS mutation has a negative prognostic impact especially in early stage LADC20–22.
Beside its general prognostic role, the predictive value of KRAS mutational status in chemotherapy remains 
controversial17. Recently, a meta-analysis including 1677 advanced NSCLC patients revealed that patients 
with KRAS mutations had significantly lower ORR and potentially lower PFS after first-line chemotherapy23. 
Furthermore, the presence of KRAS mutations had a mild negative impact on OS in advanced NSCLC patients 
treated with first-line chemotherapy in 52 Italian institutions24. A retrospective analysis of 484 Asian advanced 
NSCLC patients showed only limited predictive role of KRAS mutation25. Additionally, several other studies 
failed to show a predictive role of KRAS mutation for first-line chemotherapy efficacy26–28.
Importantly, however, there is limited data available regarding the influence of KRAS mutation on the organ 
specificity of LADC metastases29–31. Nevertheless, KRAS mutation might have different prognostic or predictive 
role depending on the site of dissemination. For this very reason, the aim of our study was to investigate the met-
astatic site-specific prognostic value of KRAS mutation in LADC patients.
Patients and Methods
Study Population. In our retrospective analysis, 532 consecutive Caucasian patients with cytologically or 
histologically verified stage IV LADC were included at the National Koranyi Institute of Pulmonology and at 
the Department of Pulmonology, Semmelweis University between January 2009 and March 2013. All patients 
were (re)staged using the 7th edition of the TNM classification32. Age, Eastern Cooperative Oncology Group 
Performance Status (ECOG PS), smoking status, TNM stage and metastatic pattern was evaluated at the 
time of diagnosis. We differentiated single-organ and multiple-organ metastatic cases. Clinical follow-up was 
closed on the 1st of May, 2015. The study and all treatments were conducted in accordance with the current 
National Comprehensive Cancer Network guidelines, based on the ethical standards prescribed by the Helsinki 
Declaration of the World Medical Association and with the approval of the Scientific and Research Committee of 
the Hungarian Medical Research Council (52614–4/2013/EKU), which waived the need for individual informed 
consent for this retrospective study. Thirty-two patients with known EGFR mutations were excluded and the 
remaining 500 were analyzed within this study.
Molecular testing. Based on the knowledge that KRAS, EGFR and ALK (anaplastic lymphoma kinase) 
mutations are mutually exclusive (with rare reported exceptions)6, in Hungary KRAS testing is performed at first 
in all adenocarcinoma or adenosquamous cases to exclude KRAS-mutant cases from EGFR analysis as part of a 
diagnostic algorithm. This screening strategy results in a large number of cases with KRAS mutation data.
All mutational analyses were performed at the 2nd Department of Pathology and at the 1st Department of 
Pathology and Experimental Cancer Research, Semmelweis University as previously described33. According to 
the contemporary National Comprehensive Cancer Network (NCCN) guideline34, DNA isolation was performed 
from formalin fixed paraffin-embedded (FFPE) tissue blocks or cytological specimens of primary tumors or lym-
phatic or organ metastases (including pleural effusion).
KRAS mutations were identified by microcapillary-based restriction fragment length analysis as described5. 
Briefly, tumor-rich microscopic area on H&E staining had been determined by pathologists prior to macrodissection 
from FFPE tissue or cytological smears. DNA was extracted using the MasterPure™ DNA Purification Kit (Epicentre 
Biotechnologies, WI) according to the instructions of the manufacturer. The microfluid-based restriction fragment 
detection system characterized by 5% mutant tumor cell content sensitivity. Density ratio of the mutated band to the 
WT one was calculated and samples containing > 5% of the non-WT band were considered mutation positive due to 
the sensitivity threshold. The base-pair substitution in the mutant samples were verified and determined by sequenc-
ing on the ABI 3130 Genetic Analyzer System (Life Technologies, Carlsbad, CA) with the BigDye® Terminator v1.1 
Kit. EGFR mutation analysis was performed by Sanger Sequencing of the EGFR exon 18–21 as previously described4.
Statistical Methods. Categorical parameters (gender (female vs male), smoking status (never- vs ever (for-
mer and current)-smoker, ECOG PS (0 vs 1), and KRAS mutation status (mutant vs wild-type)) of the patients 
cohorts with different organ specific metastatic pattern (lung, bone, adrenal, brain, pleura, and liver) were sta-
tistically analyzed by Chi-square test. Age as a continuous variable was analyzed in the different single-organ 
metastatic groups by Student’s t-test. Kaplan-Meier survival curves and two-sided log-rank tests were used for 
univariate survival analyses. The Cox proportional hazards model was used for univariate survival analyses to 
calculate the hazard ratios (HR) and corresponding 95% confidence intervals (CI). P values are always given as 
two-sided and were considered statistically significant below 0.05. Metric data is always shown as median or mean 
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and corresponding range or, in case of OS, as median and corresponding 95% CI. All statistical analyses were 
performed using the PASW Statistics 18.0 package (Predictive Analytics Software, SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics and metastatic pattern. Clinicopathological characteristics of patients with 
different metastatic pattern are shown in Table 1. We found 362 (72%) patients with single-organ metastatic 
disease and 138 (28%) cases with metastases affecting multiple organs (Table 1). The most frequent metastatic 
sites included lung (45.6%), bone (26.2%), adrenal gland (17.4%), brain (16.8%), pleura (15.6%), and liver (11%).
We did not find significant differences in age between the single-organ (62.3 ± 9.3) vs multiple-organ 
(60.8 ± 9.7) metastatic cohorts. Patients presented with only pleural spread (66.8 ± 10.4) were significantly 
older than those with only lung (62 ± 8.9), bone (60 ± 10.7), adrenal (63.1 ± 6.8) or brain (59.7 ± 9.2) metastases 
Metastatic site Total Single-organ Multiple-organ Lung* Bone* Adrenal* Brain* Pleura* Liver*
Number of patients 500 362** 138 228 131 87 84 78 55
Single-organ only 152 50 38 53 43 16
Age (mean ± SD) 61.9 ± 9.4 62.3 ± 9.3 60.8 ± 9.7 62 ± 8.9 60 ± 10.7 63.1 ± 6.8 59.7 ± 9.2 66.8 ± 10.4 64.4 ± 9.1
Gender
Male 245 (49%) 181 (50%) 64 (46%) 102 (45%) 74 (56%) 34 (39%) 36 (43%) 38 (49%) 26 (47%)
Female 255 (51%) 181 (50%) 74 (54%) 126 (55%) 57 (44%) 53 (61%) 48 (57%) 40 (51%) 29 (53%)
ECOG PS
0–1 459 (94%) 335 (94%) 124 (92%) 218 (97%) 115 (91%) 75 (87%) 77 (93%) 71 (91%) 48 (91%)
> 1 32 (6%) 21 (6%) 11 (8%) 7 (3%) 11 (9%) 11 (13%) 6 (7%) 7 (9%) 5 (9%)
Unknown 9 6 3 3 5 1 1 0 2
Smoking
Never 67 (15%) 52 (16%) 15 (12%) 29 (14%) 18 (16%) 7 (9%) 7 (9%) 20 (27%) 4 (8%)
Former 141 (31%) 104 (31%) 37 (30%) 61 (29%) 32 (28%) 20 (25%) 25 (32%) 23 (32%) 20 (41%)
Current 250 (54%) 179 (53%) 71 (58%) 117 (57%) 65 (58%) 52 (66%) 45 (58%) 30 (41%) 25 (51%)
Unknown 42 27 15 21 16 8 7 5 6
KRAS
Wild-type 357 (71%) 263 (73%) 94 (68%) 148 (65%) 94 (72%) 58 (67%) 60 (71%) 65 (83%) 46 (84%)
Mutant 143 (29%) 99 (27%) 44 (32%) 80 (35%) 37 (28%) 29 (33%) 24 (29%) 13 (17%) 9 (16%)
***Median OS (months) 10.8 11.67 6.87 15.6*** 7.9*** 14.4*** 10.3*** 8.8*** 8.9***
Table 1.  Clinicopathological characteristics, overall survival (OS), KRAS mutational status and metastatic 
pattern in lung adenocarcinoma patients. *Values include both single- and multiple-organ cases except for 
OS. **In 10 cases, other than the listed types of metastasis was present (renal and subcutaneous). ***Only 
single-organ metastatic patients were included. Data shown in parentheses are column percentages; ECOG PS, 
Eastern Cooperative Oncology Group performance status; OS, overall survival.
Figure 1. Metastatic site-specific variation of KRAS status. (A) Patients with multiple-organ metastases showed 
a non-significant increase in the percentage of KRAS mutant cases (vs single-organ spread, 32% v 27%). (B) In 
the organ-specific analysis, patients with brain, bone or adrenal gland metastases demonstrated similar KRAS 
mutation frequencies (29%, 28% and 33%, respectively). However, pulmonary metastatic cases demonstrated 
increased KRAS mutation frequency when compared to those with extrapulmonary metastases (35% and 26.5%; 
p = 0.0125). In contrast, pleural dissemination and liver metastasis associated with decreased KRAS mutation 
incidence (17% (p < 0.001) and 16% (p = 0.0023), respectively).
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(p = 0.0024, p = 0.0008, p = 0.0132, p = 0.002, respectively). Patients with brain involvement were significantly 
younger than those with lung metastasis (p = 0.0094).
The proportion of patients with ECOG PS 0–1 was similar in the different organ-specific metastatic sub-
groups. Of note, we found significantly higher numbers of never-smokers in the subgroup of patients with pleural 
metastases (27%) when compared to all other sites (12.2%, p = 0.0018).
Metastatic site-specific variation of KRAS status. KRAS mutation incidence was 28.6% in the full 
cohort. Patients with multiple-organ metastases showed a non-significant increase in the percentage of KRAS 
mutation (vs single-organ spread, 32% vs 27%, Table 1, Fig. 1A). Metastatic site-specific variation of KRAS status 
is shown in Fig. 1. Importantly, patients with brain (29%), bone (28%) or adrenal gland (33%) metastases demon-
strated similar KRAS mutation frequencies (Table 1, Fig. 1B). However, pulmonary metastatic cases demonstrated 
increased KRAS mutation frequency when compared to those with all extrapulmonary metastases (35% and 
26.5%, p = 0.0125, Fig. 1B). In contrast, pleural dissemination and liver metastasis were associated with decreased 
KRAS mutation incidence (vs all other metastatic sites; 17% (p < 0.001) and 16% (p = 0.0023), respectively).
Clinical Outcome. Patients with multiple-organ metastases had significantly decreased median overall sur-
vival (OS) compared to those with single-organ metastasis (6.8 vs 11.6 months, respectively; HR, 95% CI, 0.6262, 
0.498 to 0.788, p < 0.001, Fig. 2A). Next, we compared the prognostic impact of single-organ metastatic sites 
(Fig. 2B). Patients with single-organ metastasis limited to the pleura demonstrated significantly decreased OS 
when compared to those with lung-only (median OS, 7.5 vs 15.6 months, HR, 0.460, 95% CI, 0.255 to 0.646; 
p < 0.001) or with adrenal-only spread (median OS, 7.5 vs 14.4 months, HR, 1.896, 95% CI, 1.154 to 3.114; 
p = 0.011). Furthermore, patients with brain metastasis showed significantly decreased OS when compared to 
patients presented with lung metastasis (median OS, 10.3 vs15.6 months, respectively; HR, 1.5; 95% CI, 1.004 to 
2.117; p = 0.04). There was no statistically significant difference in other organ specific comparison.
Figure 2. Kaplan-Meier curves for the OS of lung adenocarcinoma patients according to metastatic sites 
and KRAS mutation status. (A) Patients with multiple-organ metastases had significantly decreased median 
overall survival (OS) compared to those with single-organ metastasis (6.8 vs 11.6 months; HR, 0.62; 95% CI, 
0.498 to 0.788; p < 0.001). (B) In the comparison of single-organ sites, patients presented with single-organ 
metastasis to the pleura demonstrated significantly decreased median OS when compared to those with lung 
(7.5 vs 15.6 months; HR, 0.460; 95% CI, 0.255 to 0.646; p < 0.001) or adrenal spread (7.5 vs 14.4 months; HR, 
1.896; 95% CI, 1.154 to 3.114; p = 0.011). Furthermore, patients with brain metastasis showed significantly 
decreased OS when compared to patients presented with lung metastasis (median OS, 10.3 vs 15.6 months, 
respectively; HR, 1.5; 95% CI, 1.004 to 2.117; p = 0.04). We found no statistically significant information in any 
other organ specific comparison. KRAS mutation had no significant prognostic effect (C) in the full cohort of 
metastatic stage patients at diagnosis or according to (D) patients with single or multiple-organ spreads.
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Next, we investigated the impact of KRAS mutation status on OS in the metastatic cohort (Fig. 2C) including 
the comparison of multiple- and single-organ metastatic subgroups (Fig. 2D). Importantly, we found no statisti-
cally significant information in these comparisons.
The impact of KRAS mutation status on OS of patients with different organ-specific metastases (including 
both multiple- and single-organ metastatic patients) is shown in Fig. 3. We observed a significant and clinically 
relevant decrease in OS in patients with KRAS-mutant tumors and with bone involvement (notably, this subcohort 
included bone metastastatic cases with or without non-skeletal metastasis) (vs those with KRAS-WT tumors and 
bone involvement; median OS 3.7 v 9.7 months, respectively; HR, 0.49; 95% CI, 0.31 to 0.79; p = 0.003; Fig. 3B). 
Of note, no further statistically significant differences were observed in any other organ-specific comparison. 
Moreover, KRAS-mutant lung adenocarcinoma patients with dissemination limited to the skeletal system (n = 13) 
tended to have a shorter OS then those with KRAS-WT tumors (7.0 vs 10.2 months; p = 0.21, Supplemental Fig. 1).
Discussion
Despite of the extensive research, the prognostic and predictive power and thus the clinical utility of KRAS onco-
genic mutations in lung adenocarcinoma has not yet been defined for over a decade5,17,35,36. Surprisingly, there is 
very limited comprehensive data available regarding the influence of KRAS mutation on the organ specificity of 
lung adenocarcinoma metastases37.
Figure 3. Kaplan-Meier curves for the OS of metastatic lung adenocarcinoma patients according to KRAS 
mutation status in patients with (A) lung, (B) bone, (C) adrenal, (D) brain, (E) pleura, and (F) liver spread. Both 
single- and multiple-organ metastatic cases were included in these analyses. We found a clinically relevant and 
also significant decrease in OS in patients presented with KRAS mutant bone metastasis (vs KRAS wild-type, 
median OS 3.7 v 9.7 months; HR, 0.49; 95% CI, 0.31 to 0.79; p = 0.003). Importantly, we found no statistically 
significant information in any other organ-specific comparison.
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In line with other studies, we detected a significant decrease of median OS in patients with multiple-organ 
metastases38. This observation further supports the proposal that NSCLC staging should take into account the 
number and site of metastases since tumors with a single metastasis in a single organ had significantly better 
prognosis than those with multiple metastases in one or several organs39.
Comparing single-organ metastatic cases, we found that patients presented with metastasis to the pleura and 
brain showed significantly decreased OS when compared to patients exhibited lung metastasis. Earlier studies also 
showed that brain metastasis have an increased negative impact on survival40,41.
The KRAS mutation rate in the presented cohort (28.6%) is in line with other studies17,42. Patients with 
multiple-organ metastases showed a modest increase in the incidence of KRAS mutation. While there is no 
published data for lung adenocarcinoma, significantly increased frequency of KRAS mutation in patients with 
multiple organ metastases was found in a colorectal cancer study43. With regards to metastatic sites, in line with 
previous findings of Doebele et al.37, in our study patients with brain, bone or adrenal gland metastases demon-
strated similar KRAS mutation frequencies. We detected 28% KRAS mutation frequency in the bone metastatic 
cohort which is similar to previous findings of Confavreux et al. and Bittner et al.44,45. However, we found pleural 
dissemination and liver metastasis associated with decreased and intrapulmonary with increased KRAS mutation 
incidence of the primary. Importantly, in accordance with our study, in colorectal cancer, RAS mutation was asso-
ciated with increased lung9,13 and decreased liver metastatic capacity43,46. Nevertheless, further prospective studies 
are required to conclude if KRAS status can be used to risk stratify patients for the onset of pulmonary metastasis.
With regards to KRAS mutation status and the role of smoking in pulmonary metastasis, we found no asso-
ciation between metastatic pulmonary nodules and smoking. In previous studies, smoking was found not to be a 
significant risk factor in developing lung metastases in colorectal cancer either47–49. In contrast, in esophageal and 
breast cancer, smoking was reported to be associated with pulmonary spread50,51.
In line with other studies, we found a significant decrease of median OS in patients with multiple-organ 
metastases38. Our finding further supports the proposal that the M stage should take into account the number of 
metastases and the number of metastatic sites as tumors with a single metastasis in a single organ had significantly 
better prognosis than those with multiple metastases in one or several organs39.
To the best of our knowledge, this is the first study to directly compare the prognostic role of KRAS mutations 
in the distinct metastatic sites in lung adenocarcinoma. Importantly, we demonstrated a significant and also 
clinically relevant decrease in the OS of patients with KRAS-mutant lung adenocarcinoma and bone metastasis. 
The differences between the clinicopathological characteristics of KRAS-WT and KRAS-mutant bone-metastatic 
patients cannot explain the observed decrease in OS. Of note, we found higher frequency of multiple-organ 
metastases in KRAS-WT patients presenting with bone metastases when compared to KRAS-mutant cases (84% 
v46%, p < 0.0001).
Our study has several limitations, in part due to its retrospective nature. Although we excluded EGFR mutants 
from our study, the KRAS-WT cohort was not analyzed for additional oncogenic driver mutations. In addition, 
reflecting the routine clinical practice the majority of patients are evaluated by clinical and not pathological TNM 
staging. Accordingly, we are not able to exclude the presence of asymptomatic disease or micro metastases. It is 
important to mention that in the case of the relatively less frequent metastatic site with the lowest KRAS mutation 
incidence, namely in the liver metastasis subgroup, we do not have sufficient statistical power to determine the 
impact of KRAS mutation on overall survival.
Despite enormous attempts the prognostic value and the clinical utility of the most frequently occurring 
oncogene have not been established in advanced stage lung adenocarcinoma for over a decade. Consequently, 
guidelines lack information on the clinical benefit of KRAS mutation testing in NSCLC. Therefore, and more 
importantly, our study addresses an important issue and highlights the possible prognostic importance and poten-
tial clinical relevance of KRAS mutation. In addition, our study is the first that showed metastatic site-specific var-
iation of the prognostic value of KRAS status in lung adenocarcinoma. We suggest the KRAS mutation status may 
have important implications for diagnostic strategies and treatment decisions. Our results indicate that KRAS 
mutation status has a strong prognostic value in bone metastatic lung adenocarcinoma patients. Nevertheless, 
additional studies are needed to evaluate the ability of KRAS mutation analysis to risk stratify patients with bone 
metastasis. Future studies are also required to investigate whether KRAS status might even predict response to 
various treatment options for bone metastatic patients.
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